Viewray (VRAY) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Viewray (VRAYResearch Report) today and set a price target of $12. The company’s shares closed yesterday at $6.77.

Yang noted:

“We believe the management is making progress in realigning/expanding internal resources to enable further operational efficiencies.”

According to, Yang is a 5-star analyst with an average return of 10.5% and a 41.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viewray with a $13.40 average price target, a 97.9% upside from current levels. In a report issued on May 1, B.Riley FBR also reiterated a Buy rating on the stock with a $12 price target.

See today’s analyst top recommended stocks >>

Based on Viewray’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $16.74 million. In comparison, last year the company had a GAAP net loss of $4.81 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.